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and Christine L. Willis *a
Kalimantacin A and batumin exhibit potent and selective antibiotic activity against Staphylococcus species
including MRSA. Both compounds are formed via a hybrid polyketide synthase/non-ribosomal peptide
synthetase (PKS-NRPS) biosynthetic pathway and from comparison of the gene clusters it is apparent that
batumin from Pseudomonas batumici and kalimantacin from P. ﬂuorescens are the same compound. The
linear structure of this unsaturated acid was assigned by spectroscopic methods, but the relative and
absolute stereochemistry of the ﬁve stereocentres remained unknown. Herein we describe isolation of
kalimantacin A and two further metabolites 17,19-diol 2 and 27-descarbomyl hydroxyketone 3 from cultures
of P. ﬂuorescens. Their absolute and relative stereochemistries are rigorously determined using
a multidisciplinary approach combining natural product degradation and fragment synthesis with
bioinformatics and NMR spectroscopy. Diol 2 has the 5R, 15S, 17S, 19R, 26R, 27R conﬁguration and is the
immediate biosynthetic precursor of the bioactive kalimantacin A formed by oxidation of the 17-alcohol to
the ketone.Introduction
Polyketides isolated from bacteria exhibit a range of important
bioactivities making them attractive leads for the development
of therapeutics,1 for example mupirocin is used worldwide as
a topical antibiotic.2 These compounds are eﬃciently assem-
bled in the host microorganism via sophisticated multiple
enzyme architectures known as modular polyketide synthases.
The rational alteration of these biosynthetic pathways oﬀers
exciting opportunities to access novel bioactive agents.3
In the course of a screening program for novel antibiotics,
the kalimantacins were isolated from cultures of Alcaligenes sp.
YL-02632S and the major metabolite, kalimantacin A 1 was
shown to exhibit activity against Gram-positive bacteria
including MRSA (Scheme 1).4,5, Cantock's Close, Bristol BS8 1TS, UK.
Leuven B-3001, Belgium
l, Bristol BS8 1TD, UK
ESI) available: Complete description of
ables, gures and schemes including
pounds. See DOI: 10.1039/c7sc01670k
ry, University of Warwick, Coventry CV4
Chemistry 2017A short time later the antibiotic batumin was isolated from
Pseudomonas batumici and found to have the same molecular
weight and spectroscopic properties as kalimantacin A.6,7
Batumin has been patented in the Ukraine and formulated as
Diastaf and used to detect staphylococci by taking advantage of
its selectivity for these strains.8 Decreased biolm formation
has also been reported for the majority of S. aureus strains
investigated9 and it has been found to reduce nasal S. aureus
carriage.10 Peschel and co-workers have recently highlighted the
potential scope of narrow spectrum antibiotics in the control of
bacterial populations.11
In 2010 Lavigne and co-workers isolated a metabolite from
cultures of Pseudomonas uorescens BCCM_ID9359 which again
had spectroscopic properties in accord with the structure of
kalimantacin and batumin hence it was named kal/bat
(Scheme 1). The kal/bat gene cluster was identied and char-
acterized and shown to consist of 16 open reading frames
encoding a hybrid modular polyketide synthase/non-ribosomal
peptide synthetase (PKS-NRPS) system.12,13 It has recently been
established that the biosynthetic gene clusters of kalimantacin
from P. uorescens and batumin from P. batumici14,15 are iden-
tical, conrming that they both produce the same natural
product based on a structural framework assembled on a linear
unsaturated acid featuring ve stereocenters. The PKS-NRPS is
a member of the trans-acyltransferase (AT) class of modular
polyketide synthases that lack integral AT-domains wherebyChem. Sci.
Scheme 1 Proposed ﬁnal stages of the biosynthesis of kalimantacin A.
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View Article Onlinethey gain AT and other tailoring activities in trans.16,17 This can
dramatically increase the diversity and complexity of the
chemical transformations available to the pathway and oﬀers
signicant potential for pathway engineering of new
compounds. New metabolites diol 2, with a 17-hydroxyl group
rather than carbonyl, and descarbamoyl compound 3 were
isolated by inactivation of the last two tailoring genes batF
(carbamoyl transferase) and batM (oxidoreductase) of the
P. uorescens gene cluster (Scheme 1).
The nal conversion by BatM was particularly interesting as
it transformed the almost inactive precursor, diol 2, to the
bioactive 17-ketone 1. This key step was hypothesized to be
essential for bacterial physiology whereby production of the
inactive precursor functions as a pro-drug to avoid self-
toxicity.12,13 The mode of action of kal/bat was suggested to be
inhibition of bacterial fatty acid biosynthesis, due to the pres-
ence of a FabI isoform, namely BatG and the antibiotic has high
specic activity against staphylococci.13,18 Kalimantacin/
batumin has potential value as a lead antibiotic, exhibiting
selective and high specic activity against staphylococci (MIC
value of 0.064 mg mL1) and is signicantly more active than
other antibiotics in commercial use (e.g. mupirocin MIC ca. 0.5
mg mL1).
The relative and absolute structures of kal/bat 1 and putative
biosynthetic intermediates 2 and 3 have remained elusive using
spectroscopic methods or via attempts to generate a crystalline
derivative for X-ray studies. With 32 possible isomers it is
important to determine the full structure of this antibiotic.
Herein we report a multidisciplinary approach combining
natural product isolation, chemical degradation and fragment
synthesis with bioinformatics and extensive NMR studies to
determine the relative and absolute conguration of 1 and 2
isolated from P. uorescens. For simplicity we use the name
kalimantacin.Scheme 2 Stereoselective reduction of kalimantacin A 1 and aceto-
nide formation.Results and discussion
Initially, preparative amounts of pure kalimantacin A 1 were
isolated from P. uorescens for degradation and derivatization
studies. We found that higher titres were obtained by growing
cultures in a modied L-medium rather than a tryptose broth
supplemented with sucrose and glycine as reported previ-
ously.12 The natural product was readily puried, using either
normal phase followed by reversed phase silica chromatographyChem. Sci.or HPLC to yield typically 50mg L1 of kalimantacin A. A similar
protocol was used to grow the DbatF and DbatM mutants of
P. uorescens giving biosynthetic intermediates 2 and 3. The
spectral data of 1, 2 and 3 were in accord with those reported
previously12 and these compounds were found to be stable for
several weeks at room temperature.
The rst structural investigation was the relative stereo-
chemistry of the 17,19-diol in 2 isolated from the DbatMmutant
of P. uorescens. Directed reductions19,20 of the b-hydroxyketone
moiety of kalimantacin A 1 gave 1,3-syn and 1,3-anti diols 4 and
5 for comparison with diol 2 (Scheme 2). The optical rotation of
synthetic anti diol 5, [a]D 10.0 and natural product 2, [a]D
10.4 correlated well and their 1H and 13C NMR spectra were
identical. In contrast 1,3-syn diol 4 with [a]D 5.9 showed
signicant diﬀerences in the chemical shis of C-17 (dc 68.4
for 2, dc 70.3 for 4) and C-19 (dc 66.3 for 2, dc 72.0 for 4) (Tables 1
and 2, ESI†).
The assignment of the relative stereochemistry of the 1,3-syn
and 1,3-anti diols 4 and 5 was conrmed using the method ofThis journal is © The Royal Society of Chemistry 2017
Scheme 3 Oxidative cleavage of diol 2.
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View Article OnlineRychnovsky and Evans21 from the characteristic quaternary and
methyl group 13C chemical shis of the corresponding aceto-
nides 6 and 7 (Scheme 2). Similarly the natural diol 2 was
converted to its acetonide and was the same by NMR to 7 con-
rming the anti relationship in the 17,19 diol. Bioinformatic
analysis of active site motifs of the appropriate modular ketor-
eductase (KR) domains predicts that the 17-alcohol should be
introduced with the “R” conguration on reduction of the b-
keto–thiol ester assembly intermediate.12 Hence taking into
account the Cahn–Prelog–Ingold priority change upon further
chain elongation, we made a preliminary assignment of the
absolute conguration for diol 2 as 17S, 19R.
Sequence analysis of the relevant KR domain suggested the R
conguration at C27 but this, as well as the relative stereo-
chemistry of C26 and C27, remained to be proven.12 Thus, two
fragment mimics, (2R,3R,20R)-diol 8 and (2S,3R,20R)-diol 9, of
kalimantacin A were prepared and varied in the conguration of
the 2-methyl groups (see ESI for synthetic details†). Their NMR
spectra were compared with those of the descarbamoyl metabo-
lite 3 isolated from theDbatFmutant of P. uorescens and the best
t was with (2R,3R,20R)-diol 8 (Fig. 1). To support the proposed
relative stereochemistry of the 19-alcohol and 26,27-stereo-
centres, the analogous (2R,3R,20S)-diol was also synthesized and,
as expected, the NMR data of this compound gave a poor t with
the natural product 3 (ESI, Tables 3 and 4, Fig. S2 and S3†).
With the above information in hand, it was necessary to
determine the conguration of the C-15 stereocenter as well as
conrm the tentative assignment of absolute stereochemistry
(17S, 19R, 26R, 27R) for diol 2. We turned to natural product
degradation and comparison with a synthetic standard (Scheme
3). Ozonolysis of diol 2 followed by treatment with AcOH/H2O2
led to cleavage of the 12,13-double bond to give a dihydroxy acidFig. 1 1H NMR data comparison for synthetic fragments 8 and 9 with
27-descarbamoyl metabolite 3.
This journal is © The Royal Society of Chemistry 2017which cyclized, aer purication by HPLC, to give lactone 10 as
a single diastereomer with [a]D +25.0.
From a combination of TOCSY and NOESY it was apparent
that the ring adopted a boat conformation with NOESY corre-
lations from 5-H to 2a-H, 4a-H and 3-CH3 consistent with these
being on the same face of the molecule (Fig. 2). A NOESY
correlation between 2b-H and 3-H, which was in accord with the
methyl group at C-3 having a relative anti relationship with the
C-5 side-chain so that in the ‘open chain structure’ it would have
a syn relationship with the C-5 alcohol.
Further support came from comparing the coupling
constants for the ring protons in lactone 10 with those reported
for anti and syn lactones 11 and 1222 (Fig. 2). The signals
assigned to 4-H2 in 11 and 12 have signicantly diﬀerent
couplings constants and the NMR data for anti lactone 11
correlated well with those for degradation product 10.
The deduced structure and absolute conguration of
degradation product 10 were conrmed by total synthesis
(Schemes 4 and 5). Addition of a copper mediated Grignard
reagent to chiral crotonate 13 using the conditions reported by
Lipshutz23 gave the known allylated sultam 14 generating the 3-
methyl stereocenter in the target lactone. Oxidative cleavage of
the alkene using OsO4/NaIO4 in the presence of 2,6-lutidine24
followed by reduction of the resultant aldehyde gave alcohol 15
in quantitative yield. Addition of lutidine was important as
without it only a 15% yield of aldehyde was obtained. Protection
of alcohol 15 as the TBS ether and reductive cleavage of the
auxiliary gave an aldehyde which was immediately subjected to
Brown allylation conditions with (+)-DIP-Cl25,26 giving alkene 16
in 83% yield over the 3 steps. The stereochemical outcome
of the reaction was conrmed by analysis of the (R)- and
(S)-Mosher's ester27,28 derivatives of alcohol 16.Fig. 2 Selected NMR coupling constants for lactones 10, 11 and 12 and
nOe correlations for 10.
Chem. Sci.
Scheme 4 Synthesis of amine 22.
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View Article OnlineNext the amine and the further required protected alcohol
were introduced via manipulation of the terminal alkene of 16
(Scheme 4). 1-Azido-2-trimethylsiloxanes have been prepared via
kinetic resolution of terminal epoxides using TMSN3 and a chiral
bidentate salen ligand.29 Thus alcohol 16 was protected as the
TBS ether then treatment with MCPBA gave a 1.7 : 1 mixture of
epoxides 17 and 18 in 81% yield. The mixture was treated with
chiral salen complex 19 and TMSN3 giving azide 20 (62%) and
unreacted epoxide 18 (31%) which were readily separated by
column chromatography. The anti relationship of the protected
1,3-diol was conrmed by deprotection of silyl ether 20 and
conversion of the resultant anti 1,3-diol to acetonide 21 which
gave characteristic 13C NMR signals at dc 100 for the quaternaryScheme 5 Preparation of lactone 10.
Chem. Sci.carbon and dc 24.7, 24.8 for the methyl groups. TBS protection of
secondary alcohol 20 and reduction of the azide gave amine 22
required for coupling to the butanoic acid derivative.
Acid 23 was readily prepared from ethyl (2R,3R)-3-hydroxy-2-
methylbutanoate30,31 via formation of the p-methoxybenzyl ether
followed by hydrolysis of the ester with barium hydroxide
(Scheme 5). Amine 22 and acid 23 were coupled giving 24 with
the required carbon framework of the target lactone. Further
functional groupmanipulations included selective deprotection
of the primary silyl ether 24 then a two-step oxidation protocol
to give carboxylic acid 25 using DMP followed by a Pinnick
oxidation.32
Treatment of 25 with 1% HCl in EtOH generated lactone 26.
To complete the synthesis of 10 the secondary alcohol in 26 was
protected as the silyl ether and the benzyl ether removed with
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) giving 27. The
carbamoyl group was introduced using tri-
chloroacetylisocyanate in CH2Cl2 followed by stirring with
alumina to give 28 in 76% yield. Finally removal of the silyl ether
with 1% HCl in EtOH gave lactone 10.
The 1H- and 13C NMR data of synthetic lactone 10 and the
product isolated from ozonolysis of metabolite 2 were the same
(Table 5, ESI†). Furthermore the optical rotation of the two
samples were entirely consistent. Thus, we can conrm the
absolute and relative conguration of the C14–C28 fragment of
diol 2 is as shown in Scheme 5.
The nal challenge was to determine the stereochemistry of
the remote C-5 stereocentre. We again applied a combination of
degradation studies and chemical synthesis. Diol 2 was meth-
ylated with TMS diazomethane then treated with 2nd generation
Hoveyda–Grubbs catalyst33 under an ethylene atmosphere to
give the degradation product ()-29 with [a]D 6.8 (Scheme 6).
The absolute conguration of 29 was conrmed via the
enantioselective synthesis shown in Scheme 7. The stereocentre
which would become C-5 in the target was readily generated via
an alkylation reaction with NaHMDS/CH3I giving oxazolidinone
30 as previously described.34 Following reductive cleavage of the
auxiliary, primary alcohol 31 was converted to iodide 32.
The key synthetic step was formation of the tri-substituted
unsaturated ester 33. Preliminary studies using Horner–Wads-
worth–Emmons or Julia chain extensions of a methyl ketone
proved unsatisfactory giving a mixture of E and Z-alkenes.This journal is © The Royal Society of Chemistry 2017
Scheme 6 Methylation of diol 2 followed by degradation to ester
()-29.
Scheme 7 Enantioselective synthesis of ester (+)-29 and ﬁnal
assignment of diol 2.
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
Ju
ly
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
7/
07
/2
01
7 
14
:0
8:
41
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineHowever, excellent control of alkene geometry was achieved via
addition of the cuprate derived from iodide 32 to commercially
available methyl but-2-ynoate. Following work up and depro-
tection, primary alcohol 33 was isolated in 71% yield from
iodide 32 and the E-alkene geometry was conrmed by nOe.
Aldehyde 34, prepared by Dess–Martin periodinane
(DMP) oxidation35 of alcohol 33, was coupled with but-3-
enylmagnesium bromide and further oxidation gave ketone 35
in 52% yield over the 3 steps. In the nal methylenation step it
was important to avoid bond migration of the exo alkene to an
endo position. This was achieved via the zirconium-mediatedThis journal is © The Royal Society of Chemistry 2017methylenation36,37 of the ketone. Unsaturated methyl ester
(+)-29 had identical NMR spectra to the degradation product
()-29 but with an optical rotation [a]D +5.0 in accord with the
synthetic material being the enantiomer of the degradation
product. Thus kalimantacin A 1 has the 5R conguration.Conclusions
In conclusion, elucidating the absolute conguration of
complex polyketides with multiple stereogenic centers is oen
an ambitious undertaking.38,39 Herein we used a multidisci-
plinary approach involving natural product isolation, chemical
degradation studies, bioinformatics, NMR correlations and
fragment synthesis to rigorously determine the absolute and
relative stereochemistry of the kalimantacins isolated from P.
uorescens. Diol 2 from the DbatM mutant has the 5R, 15S, 17S,
19R, 26R, 27R stereochemistry and is the immediate biosyn-
thetic precursor of the bioactive kalimantacin A 1 formed by
oxidation of the secondary alcohol to the 17-ketone. The abso-
lute congurations of the 17, 19 and 27-hydroxyl groups in diol
2 are in good agreement with bioinformatic predictions.12,13
The 13C and 1H NMR data for natural product 1 isolated from
P. uorescens are entirely consistent with those reported4,5 for
kalimantacin from Alcaligenes sp. YL-02632S in accord with
both structures having the same relative stereochemistry.
Furthermore it is evident from comparison of PKS/NRPS gene
clusters for kalimantacin A from cultures of P. uorescens12 and
batumin from P. batumici14 that the natural products are indeed
the same compound. Synergising chemical and biochemical
methods have led to the elucidation of the structures of kali-
mantacin A 1 (and hence batumin) and diol 2.
The inexorable rise of antibiotic resistant bacteria requires
a multi-facetted response to meet this global threat to human
health. In contrast to broad spectrum antibiotics, narrow
spectrum agents can selectively decolonise specic pathogens
(so called decolonisation drugs) in the human microbiota and
are becoming increasingly important for detecting as well as
ghting specic infections. They may also reduce the chance of
emergence of antibiotic resistant strains.11 Kalimantacin has
been identied as a highly specic agent against staphylococci
that will potentially allow its deployment for the detection of
resistant strains as well as a potent decolonisation agent. The
determination of the absolute stereochemistry of kalimantacin
as described in this paper will underpin further functional
investigation of this important molecule.Acknowledgements
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